Volume 22 Issue 12, December 2023

Ventus has overcome medicinal chemistry challenges to advance a first inhibitor of cGAS-STING into the clinic, as drug developers build the case for novel anti-inflammatory agents in autoimmune diseases including lupus.

New classes of antibiotic with activity against Gram-negative bacteria that are resistant to existing drugs are urgently needed, but have been very challenging to identify. This Review describes promising but as-yet-unrealized targets for antibacterial drugs against Gram-negative bacteria and highlights lessons learned from past drug discovery programmes.

This Review discusses current research strategies to overcome resistance to CAR-T cell therapy in blood cancers, including optimization of CAR design, improvement of T cell function and persistence, modulation of the immunosuppressive tumour microenvironment and synergistic combination strategies.

T cell receptors (TCRs) enable the targeting of proteins selectively expressed by cancer cells, including neoantigens, cancer germline antigens and viral oncoproteins. This Review discusses the current cancer treatment landscape using TCRs and TCR-like molecules, including adoptive cell transfer of T cells expressing endogenous or engineered TCRs or TCR bispecific engagers.